Skip to content

Modeling sarcopenic obesity to advance healthy weight loss therapies

  • Barbora Krajnikova

Background & aim: Incretin-based therapies have revolutionized obesity treatment by substantially reducing body weight and fat mass, yet are associated with a disproportionate loss of lean mass compared with traditional weight-loss interventions. Despite the great interest in the matter, primary…

Read more

Humanizing Dyslipidemia in MASH: A PCSK9-Driven dyslipidemia GAN DIO-MASH Model

  • Henrik

Background & aim: Dyslipidemia, characterized by hyper-cholesterolemia and hypertriglyceridemia, is a central component of metabolic dysfunction-associated steatohepatitis (MASH) pathogenesis. While being highly instrumental in drug development, preclinical models of MASH often fail to recapitulate a human-like lipoprotein profile. To enhance…

Read more
Back To Top